Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldurazyme Extension Study in MPS I
NCT00146770Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2001
- Primary completion
- Mar 2005
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
Phase 3, open-label trial of laronidase in mucopolysaccharidosis type I (2 arms), sponsored by Sanofi. Primary endpoints: Percent Predicted Forced Vital Capacity at Week 182 and Six Minute Walk Test at Week 182. Started May 2001; status: completed.
02
Drugs
laronidase
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT00146770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146770.